Business model
A business model built for the future
We are full life cycle investors creating value and offering support at any stage, from academic programs all the way to mature publicly traded companies.
What we need to create value
Experienced team
A collaborative team of doctors, academics, and drug developers coupled with seasoned venture capitalists, investment bankers, lawyers and operators with a strong compliance culture.
Scientific rigor
Our research process combines wide data-gathering with deep analysis to identify the most compelling assets, technologies, and modalities with the best chance of reaching patients.
Full lifecycle investing
Taking a long-term, full-lifecycle approach and having a true evergreen structure helps us avoid the structural constraints of venture-only or public-only vehicles.
Global reach
Great science takes place everywhere in the world. Our global reach helps us find and support innovation wherever it exists.
How we create value
Our purpose drives everything we do
Identify transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by our deep scientific understanding and a long-term approach to supporting innovative businesses, we invest in companies developing next-generation therapies and technologies that can significantly improve patients’ lives.
Our purpose
We power breakthrough therapies that transform the lives of millions
Broad Value Creation
Patient Benefits
11
RTW’s top 10 most successful investments since inception have commercialized 11 drugs
Portfolio Companies
34
Number of private investments that have had a liquidity event out of 61 total
Local Communities
12
Number of community organizations and research partners the RTW Charitable Foundation supported in responding to COVID needs in New York City
Ultrarare Disease
9
Rare disease research organizations supported through RTWCF grants across six countries
RTW senior team
Roderick Wong, MD
Sabera Loughran
Naveen Yalamanchi, MD
Stephanie A. Sirota
Peter Fong, PhD
Gotham Makker, MD
Robert Aurigema
Chris Seiter
Speak to a member of our team
